Beta
Rivaroxaban
medication Under reviewA direct oral anticoagulant (DOAC) medication used to treat and prevent blood clots and reduce the risk of stroke.
Research summary
Clinical research in healthy human subjects demonstrates that rivaroxaban is well-tolerated with a predictable pharmacological profile and minimal potential for clinically relevant drug-drug interactions. Pharmacokinetic studies show dose-proportional kinetics without dose accumulation at steady state. The drug exhibits high plasma protein binding (95%), primarily to serum albumin, with minimal metabolism and unchanged rivaroxaban representing 89% of total plasma activity. Real-world efficacy and safety data from patients with venous thromboembolism and atrial fibrillation confirm the benefit-risk profile observed in clinical trials, with major bleeding rates of approximately 0.51-1.06% at 12 months depending on treatment continuation.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Rivaroxaban to your stack to report effects
Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects
Not specified in source
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Not specified in source
Two New Real-World Studies Confirm Positive Efficacy and Safety Profile of XARELTO (Rivaroxaban) in Treating and Preventing Blood Clots
Janssen Pharmaceuticals and Bayer
Real-World Data Show Consistent Safety Performance of Once-Daily Rivaroxaban
W. Frank Peacock and colleagues
No reports yet
Be the first to report this effect and help the community.
Add Rivaroxaban to your stack to report effects
Two New Real-World Studies Confirm Positive Efficacy and Safety Profile of XARELTO (Rivaroxaban) in Treating and Preventing Blood Clots
Janssen Pharmaceuticals and Bayer
Real-World Data Show Consistent Safety Performance of Once-Daily Rivaroxaban
W. Frank Peacock and colleagues
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Hypertension — elevated blood pressure requiring management
Two New Real-World Studies Confirm Positive Efficacy and Safety Profile of XARELTO (Rivaroxaban) in Treating and Preventing Blood Clots
Janssen Pharmaceuticals and Bayer
Real-World Data Show Consistent Safety Performance of Once-Daily Rivaroxaban
W. Frank Peacock and colleagues
Research (4 studies)
Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects
Not specified in source
Two New Real-World Studies Confirm Positive Efficacy and Safety Profile of XARELTO (Rivaroxaban) in Treating and Preventing Blood Clots
Janssen Pharmaceuticals and Bayer
Real-World Data Show Consistent Safety Performance of Once-Daily Rivaroxaban
W. Frank Peacock and colleagues
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Not specified in source
Community updates
No updates yet for this supplement.
Be the first to share your experience!